Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!
Tóm tắt
Analysis of subgroup results in a clinical trial is surprisingly unreliable, even in a large trial. This is the result of a combination of reduced statistical power, increased variance and the play of chance. Reliance on such analyses is likely to be more erroneous, and hence harmful, than application of the overall proportional (or relative) result in the whole trial to the estimate of absolute risk in that subgroup. Plausible explanations can usually be found for effects that are, in reality, simply due to the play of chance. When clinicians believe such subgroup analyses, there is a real danger of harm to the individual patient.
Tài liệu tham khảo
Collins R, Peto R, Gray R, Parish S: Large-scale randomized evidence: trials and overviews. In: Oxford Textbook of Medicine, edn 3. Edited by Weatherall DJ, Ledingham JGG, Warrell DA. Oxford, UK: Oxford University Press,. 1996, 21-32.
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999, 353: 611-616. 10.1016/S0140-6736(98)05012-0.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group : Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988, ii: 349-360.
The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med. 2000, 342: 145-153. 10.1056/NEJM200001203420301.
Fibrinolytic Therapy Trialists' (FTT) Collaborative Group : Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet . 1994, 343: 311-322. 10.1016/S0140-6736(94)91161-4.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis. 1985, 27: 335-371.
Effron B, Morris C: Steins paradox in statistics. Sci Am . 1977, 236: 119-127.
The GUSTO Investigators : An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993, 329: 673-682. 10.1056/NEJM199309023291001.
Sleight P: Streptokinase is still the agent of choice for most patients with myocardial infarction. Am J Ther. 1995, 2: 128-135.
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group : ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992, 339: 753-770. 10.1016/0140-6736(92)91893-D.
Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR: Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation . 2000, 101: 2239-2246.
Collins R, Peto R, Baigent C, Sleight P: Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997, 336: 847-860. 10.1056/NEJM199703203361207.